An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity

Dihydropyrimidine dehydrogenase (DPD)‐deficient patients might only become aware of their genotype after exposure to dihydropyrimidines, if testing is performed. Case reports to pharmacovigilance databases might only contain phenotypical manifestations of DPD, without information on the genotype. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Correia Pinheiro, Luis, Durand, Julie, Dogné, Jean‐Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158217/
https://www.ncbi.nlm.nih.gov/pubmed/31955411
http://dx.doi.org/10.1002/cpt.1789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158217/
https://www.ncbi.nlm.nih.gov/pubmed/31955411
http://dx.doi.org/10.1002/cpt.1789

Ejemplares similares